Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Acts upstream of or within cellular response to ionizing radiation and positive regulation of apoptotic process. Located in mitochondrion. Is expressed in several structures, including brain; hindbrain neural plate; immature eye; midbrain hindbrain boundary neural keel; and pleuroperitoneal region. Human ortholog(s) of this gene implicated in endometrial cancer; lung non-small cell carcinoma; and pancreatic cancer. Orthologous to human BAD (BCL2 associated agonist of cell death). [provided by Alliance of Genome Resources, Feb 2025]